187 related articles for article (PubMed ID: 14616955)
1. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
Pitini V; Arrigo C; Barresi G
Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
[No Abstract] [Full Text] [Related]
2. Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Dungarwalla M; Field-Smith A; Jameson C; Riley U; Chapman A; Bunker CB; Dearden CE; Matutes E
Haematologica; 2007 Jan; 92(1):e5-6. PubMed ID: 17405741
[No Abstract] [Full Text] [Related]
3. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
4. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
Smith JA
Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
[No Abstract] [Full Text] [Related]
5. Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I; Grossbard ML
Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
[No Abstract] [Full Text] [Related]
6. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
Keating M; Hallek M
Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
[No Abstract] [Full Text] [Related]
7. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
8. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
9. Campath-1H for chronic lymphocytic leukemia.
Rai KR
Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
[No Abstract] [Full Text] [Related]
10. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
[No Abstract] [Full Text] [Related]
12. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
[No Abstract] [Full Text] [Related]
13. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
[No Abstract] [Full Text] [Related]
14. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
17. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
18. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
Oberoi SS; Abou Jawde RM
J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
[No Abstract] [Full Text] [Related]
19. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
d'Arena G; de Filippi R; Pinto A
Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
[No Abstract] [Full Text] [Related]
20. Alemtuzumab for treatment of lymphoproliferative disorders.
Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
